Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM1JN6A)

Drug Name
Axovan-3 Drug Info
Indication
Disease Entry ICD 11 Status REF
Eating disorder 6B82 Discontinued in Phase 1 [1]
Obesity 5B81 Discontinued in Phase 1 [1]
Cross-matching ID
TTD Drug ID
DM1JN6A

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Neuropeptide Y receptor type 5 (NPY5R) TTY6EWA NPY5R_HUMAN Antagonist [1]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Neuropeptide Y receptor type 5 (NPY5R) DTT NPY5R 6.192 6.174 6.582 6.385
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Eating disorder
ICD Disease Classification 6B82
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Neuropeptide Y receptor type 5 (NPY5R) DTT NPY5R 7.49E-01 1.19E-02 0.03
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 Emerging drugs for eating disorder treatment. Expert Opin Emerg Drugs. 2006 May;11(2):315-36.